GlassScriptPhysician profile
John Michael Edmison
NPI 1861662421
$10,395.30
in general payments reported to CMS, 2019-2025
36 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $602 · 2021: $1,322 · 2022: $1,701 · 2023: $2,115 · 2024: $2,114 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,776.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,262.71 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $730.52 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Genzyme Corporation | $619.30 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $566.39 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $539.60 | 2020-2025 | Livdelzi |
| Celgene Corporation | $390.23 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $376.16 | 2021-2023 | Stelara |
| Janssen Biotech, INC. | $372.42 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $350.75 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $295.30 | 2021-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $232.04 | 2022-2023 | |
| Qol Medical, LLC | $219.66 | 2022-2024 | Sucraid, Sucraid |
| Allergan, INC. | $202.52 | 2019 | |
| Phathom Pharmaceuticals, INC. | $161.46 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $130.82 | 2023-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $119.54 | 2023 | Esophyx |
| Ardelyx, INC. | $107.78 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $73.73 | 2020-2024 | Injectafer |
| Intra-Sana Laboratories | $66.52 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $53.00 | 2020-2021 | |
| Redhill Biopharma INC. | $52.07 | 2020-2021 | |
| Madrigal Pharmaceuticals | $49.88 | 2025 | Rezdiffra |
| Amgen INC. | $48.85 | 2021-2023 | Avsola, Amjevita |
| Nestle Healthcare Nutrition INC. | $47.56 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $41.14 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $37.75 | 2019-2021 | |
| Lilly USA, LLC | $35.20 | 2024-2025 | Omvoh |
| Medtronic, INC. | $34.92 | 2022-2024 | Interstim |
| Echosens North America, INC. | $31.59 | 2019 | |
| Ucb, INC. | $29.87 | 2019 | |
| Boston Scientific Corporation | $27.14 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $22.98 | 2024 | Givlaari |
| Aimmune Therapeutics, INC. | $18.14 | 2025 | Zenpep |
| Shire North American Group INC | $17.68 | 2019 | |
| Laborie Medical Technologies Corp. | $17.28 | 2023 | |
| Alfasigma USA, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Edmison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.